Welcome to The Myeloma Sessions, brought to you by The Video Journal of Hematological Oncology (VJHemOnc). This exclusive session features leading experts in multiple myeloma; Mohamad Mohty, Saint-Antoine Hospital, Paris, France, Francesca Gay, University of Turin, Italy, and Saad Usmani, Levine Cancer Institute, Charlotte, NC, who debate the key updates in the diagnosis and treatment of multiple myeloma from the recent COMy, ASCO and EHA 2020 Virtual Meetings.
The topics being discussed include the management of high-risk smoldering myeloma (part 1), evolution of induction strategies in transplant-eligible patients (part 2), impact and role of MRD & practical considerations and the latest advances in relapsed/refractory myeloma (part 4).
“In principle, if you identify those patients who are really at a high risk of developing asymptomatic disease and you treat them with a proper therapy at the time where the disease is still asymptomatic, then you probably have found the small population of patients that could be cured.”
– Francesca Gay
“We believe that in hematology you win when you intervene early.”
– Mohamad Mohty
” I honestly was quite surprised with the results of the ECOG trial (ENDURANCE) that was reported, which compared VRd to KRd in the frontline setting. Many first believed that KRd is a better regimen for high-risk multiple myeloma patients in the frontline setting based on the Phase II data that’s available.”
– Saad Usmani
“By adding a drug with a totally new mechanism of action, like the anti-CD38, is bringing much more added value than just by switching the same family of drugs, proteasome inhibitors, into first generation to second generation.”
– Mohamad Mohty
“We can analyze and we can understand how can the outcome of patients who, for example, maintain a sustained MRD negativity, be affected.”
– Francesca Gay
“I’ve never met a patient who has told me, “Oh, I love continuous therapy.” And MRD, I think, definitely is the right tool to help us to refine the duration of therapy and to identify, in a dynamic fashion, the high-risk patient versus maybe the standard-risk where our approaches can move away from this long-standing one-size-fits-all.”
– Mohamad Mohty
“Once the CAR-Ts and bispecifics move to earlier lines, there’s also possibility of utilizing bispecifics in consolidation and maintenance strategy for patients not achieving the best MRD negativity.”
– Saad Usmani
“This is really a very important message, that initially we used to think that the first line is really the most important but now we are able to achieve at the level of the second and even third line, a very important duration of response and progression-free survival.”
– Mohamad Mohty
By choosing to continue, you are confirming that you are a healthcare professional
Keep up to date with all the latest news with our monthly newsletter